| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c34620c90b99fa0fe50048309ef38bce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ea5203c7c94a36da317f4e3ec368490
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c394b038e6ea703aea043d3e22ac5c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_587d32d5e58cdcbf9cef902174eaa73d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 |
| filingDate |
2007-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfd25bc79515d8264b9f1f05b5718695
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4075668f7d5fbe8f005da1da32ba0ee1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d21b480de2f756904f00f53c65a2c085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ad11ba97c7ca7e1aee343f7a69e77ec |
| publicationDate |
2009-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2029149-A1 |
| titleOfInvention |
Immune privileged and modulatory progenitor cells |
| abstract |
Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like. |
| priorityDate |
2006-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |